Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study. / Wittenbecher, C; Guasch-Ferré, M; Haslam, DE; Dennis, C; Li, J; Bhupathiraju, SN; Lee, CH; Qi, Q; Liang, L; Eliassen, AH; Clish, C; Sun, Q; Hu, FB.

In: EBioMedicine, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Wittenbecher, C, Guasch-Ferré, M, Haslam, DE, Dennis, C, Li, J, Bhupathiraju, SN, Lee, CH, Qi, Q, Liang, L, Eliassen, AH, Clish, C, Sun, Q & Hu, FB 2021, 'Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study', EBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103799

APA

Wittenbecher, C., Guasch-Ferré, M., Haslam, DE., Dennis, C., Li, J., Bhupathiraju, SN., Lee, CH., Qi, Q., Liang, L., Eliassen, AH., Clish, C., Sun, Q., & Hu, FB. (2021). Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study. EBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103799

Vancouver

Wittenbecher C, Guasch-Ferré M, Haslam DE, Dennis C, Li J, Bhupathiraju SN et al. Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study. EBioMedicine. 2021. https://doi.org/10.1016/j.ebiom.2021.103799

Author

Wittenbecher, C ; Guasch-Ferré, M ; Haslam, DE ; Dennis, C ; Li, J ; Bhupathiraju, SN ; Lee, CH ; Qi, Q ; Liang, L ; Eliassen, AH ; Clish, C ; Sun, Q ; Hu, FB. / Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study. In: EBioMedicine. 2021.

Bibtex

@article{cb9f22ccfb7a4029965ee3287347ad4c,
title = "Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study",
abstract = "BackgroundMetabolomics profiles were consistently associated with type 2 diabetes (T2D) risk, but evidence on long-term metabolite changes and T2D incidence is lacking. We examined the associations of 10-year plasma metabolite changes with subsequent T2D risk.MethodsWe conducted a nested T2D case-control study (n=244 cases, n=244 matched controls) within the Nurses' Health Study. Repeated metabolomics profiling (170 targeted metabolites) was conducted in participant blood specimens from 1989/1990 and 2000/2001, and T2D occurred between 2002 and 2008. We related 10-year metabolite changes (Δ-values) to subsequent T2D risk using conditional logistic models, adjusting for baseline metabolite levels and baseline levels and concurrent changes of BMI, diet quality, physical activity, and smoking status.FindingsThe 10-year changes of thirty-one metabolites were associated with subsequent T2D risk (false discovery rate-adjusted p-values [FDR]<0.05). The top three high T2D risk-associated 10-year changes were (odds ratio [OR] per standard deviation [SD], 95%CI): Δisoleucine (2.72, 1.97-3.79), Δleucine (2.53, 1.86-3.47), and Δvaline (1.93, 1.52-2.44); other high-risk-associated metabolite changes included alanine, tri-/diacylglycerol-fragments, short-chain acylcarnitines, phosphatidylethanolamines, some vitamins, and bile acids (ORs per SD between 1.31and 1.82). The top three low T2D risk-associated 10-year metabolite changes were (OR per SD, 95% CI): ΔN-acetylaspartic acid (0.54, 0.42-0.70), ΔC20:0 lysophosphatidylethanolamine (0.68, 0.56-0.82), and ΔC16:1 sphingomyelin (0.68, 0.56-0.83); 10-year changes of other sphingomyelins, plasmalogens, glutamine, and glycine were also associated with lower subsequent T2D risk (ORs per SD between 0.66 and 0.78).",
author = "C Wittenbecher and M Guasch-Ferr{\'e} and DE Haslam and C Dennis and J Li and SN Bhupathiraju and CH Lee and Q Qi and L Liang and AH Eliassen and C Clish and Q Sun and FB Hu",
year = "2021",
doi = "10.1016/j.ebiom.2021.103799",
language = "English",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Changes in metabolomics profiles over ten years and subsequent risk of developing type 2 diabetes: Results from the Nurses' Health Study

AU - Wittenbecher, C

AU - Guasch-Ferré, M

AU - Haslam, DE

AU - Dennis, C

AU - Li, J

AU - Bhupathiraju, SN

AU - Lee, CH

AU - Qi, Q

AU - Liang, L

AU - Eliassen, AH

AU - Clish, C

AU - Sun, Q

AU - Hu, FB

PY - 2021

Y1 - 2021

N2 - BackgroundMetabolomics profiles were consistently associated with type 2 diabetes (T2D) risk, but evidence on long-term metabolite changes and T2D incidence is lacking. We examined the associations of 10-year plasma metabolite changes with subsequent T2D risk.MethodsWe conducted a nested T2D case-control study (n=244 cases, n=244 matched controls) within the Nurses' Health Study. Repeated metabolomics profiling (170 targeted metabolites) was conducted in participant blood specimens from 1989/1990 and 2000/2001, and T2D occurred between 2002 and 2008. We related 10-year metabolite changes (Δ-values) to subsequent T2D risk using conditional logistic models, adjusting for baseline metabolite levels and baseline levels and concurrent changes of BMI, diet quality, physical activity, and smoking status.FindingsThe 10-year changes of thirty-one metabolites were associated with subsequent T2D risk (false discovery rate-adjusted p-values [FDR]<0.05). The top three high T2D risk-associated 10-year changes were (odds ratio [OR] per standard deviation [SD], 95%CI): Δisoleucine (2.72, 1.97-3.79), Δleucine (2.53, 1.86-3.47), and Δvaline (1.93, 1.52-2.44); other high-risk-associated metabolite changes included alanine, tri-/diacylglycerol-fragments, short-chain acylcarnitines, phosphatidylethanolamines, some vitamins, and bile acids (ORs per SD between 1.31and 1.82). The top three low T2D risk-associated 10-year metabolite changes were (OR per SD, 95% CI): ΔN-acetylaspartic acid (0.54, 0.42-0.70), ΔC20:0 lysophosphatidylethanolamine (0.68, 0.56-0.82), and ΔC16:1 sphingomyelin (0.68, 0.56-0.83); 10-year changes of other sphingomyelins, plasmalogens, glutamine, and glycine were also associated with lower subsequent T2D risk (ORs per SD between 0.66 and 0.78).

AB - BackgroundMetabolomics profiles were consistently associated with type 2 diabetes (T2D) risk, but evidence on long-term metabolite changes and T2D incidence is lacking. We examined the associations of 10-year plasma metabolite changes with subsequent T2D risk.MethodsWe conducted a nested T2D case-control study (n=244 cases, n=244 matched controls) within the Nurses' Health Study. Repeated metabolomics profiling (170 targeted metabolites) was conducted in participant blood specimens from 1989/1990 and 2000/2001, and T2D occurred between 2002 and 2008. We related 10-year metabolite changes (Δ-values) to subsequent T2D risk using conditional logistic models, adjusting for baseline metabolite levels and baseline levels and concurrent changes of BMI, diet quality, physical activity, and smoking status.FindingsThe 10-year changes of thirty-one metabolites were associated with subsequent T2D risk (false discovery rate-adjusted p-values [FDR]<0.05). The top three high T2D risk-associated 10-year changes were (odds ratio [OR] per standard deviation [SD], 95%CI): Δisoleucine (2.72, 1.97-3.79), Δleucine (2.53, 1.86-3.47), and Δvaline (1.93, 1.52-2.44); other high-risk-associated metabolite changes included alanine, tri-/diacylglycerol-fragments, short-chain acylcarnitines, phosphatidylethanolamines, some vitamins, and bile acids (ORs per SD between 1.31and 1.82). The top three low T2D risk-associated 10-year metabolite changes were (OR per SD, 95% CI): ΔN-acetylaspartic acid (0.54, 0.42-0.70), ΔC20:0 lysophosphatidylethanolamine (0.68, 0.56-0.82), and ΔC16:1 sphingomyelin (0.68, 0.56-0.83); 10-year changes of other sphingomyelins, plasmalogens, glutamine, and glycine were also associated with lower subsequent T2D risk (ORs per SD between 0.66 and 0.78).

U2 - 10.1016/j.ebiom.2021.103799

DO - 10.1016/j.ebiom.2021.103799

M3 - Journal article

C2 - 34979341

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -

ID: 347755974